ABPRO Holdings
web2Abpro Holdings is a clinical-stage biotechnology company developing engineered antibody therapi...
About
Abpro Holdings is a clinical-stage biotechnology company developing engineered antibody therapies for cancer and eye diseases using proprietary antibody discovery and design platforms. The company's DiversImmune and MultiMab technologies help it identify and engineer antibodies that bind selected disease targets. Its ABP-102 candidate is designed to direct immune cells against tumors expressing HER2 and is being evaluated in early clinical development with Celltrion. Another candidate, ABP-201, targets pathways involved in abnormal blood vessel growth in eye disease. Abpro develops its pipeline through internal research and partnerships with pharmaceutical companies, and its therapies remain investigational rather than approved commercial medicines.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
ABPRO Holdings profile.
Expert coverage
No published expert evaluations are available for this project yet.
Orbitrum Academy